ATIC and cancer: Additionally, three other NADBPs, which mutations are implicated in cancer, were found in the catalogue of FDA approved targets, namely, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), androgen receptor (AR) and isocitrate dehydrogenase 2 (IDH2).